Global drug giants double down on China amid trend to build self-reliant supply chains

AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants in China amid geopolitical tensions. The moves are part of a US$15 billion commitment the British firm pledged to make in the world’s second-largest drug market through 2030, unveiled during UK Prime Minister Keir Starmer’s visit to Beijing in January. China’s manufacturing capabilities, integrat...

By Julie Zhang